Abstract:A dopamine derivative, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, known as salsolinol (SAL), has increasingly gained attention since its first detection in the urine of Parkinson's disease patients treated with levodopa, and has been proposed as a possible neurotoxic contributor to the disease. Yet, so far, the neurobiological role of SAL remains unclear. Thus, the main aims of our study were to compare the neurotoxic potential of SAL with MPP + (1-methyl-4-phenylpyridinium ion) in vitro, and to examine intestinal and metabolic alterations following intraperitoneal SAL administration in vivo. In vitro, SH-SY5Y neuroblastoma cell line was monitored following MPP + and SAL treatment. In vivo, Wistar rats were subjected to SAL administration by either osmotic intraperitoneal mini-pumps or a single intraperitoneal injection, and after two weeks, biochemical and morphological parameters were assessed. SH-SY5Y cells treated with MPP + (1000 μM) and SAL (50 μM) showed increase in cell viability and fluorescence intensity in comparison with the cells treated with MPP + alone. In vivo, we predominantly observed decreased collagen content in the submucosal layer, decreased neuronal density with comparable ganglionic area in the jejunal myenteric plexus, and increased glial S100 expression in both enteric plexuses, yet with no obvious signs of inflammation. Besides, glucose and triglycerides levels were lower after single SAL-treatment (200 mg/kg), and low- to high-density lipoprotein (LDL/HDL) ratio and aspartate to alanine aminotransferases (AST/ALT) ratio levels were higher after continuous SAL-treatment (200 mg/kg in total over 2 weeks). Low doses of SAL were non-toxic and exhibited pronounced neuroprotective properties against MPP + in SH-SY5Y cell line, which supports the use of SAL as a reference compound for in vitro studies. In vivo results give insight into our understanding of gastrointestinal remodeling following intraperitoneal SAL administration, and might represent morphological correlates of a microglial-related enteric neurodegeneration and dopaminergic dysregulation.

Salidroside protected against MPP + -induced Parkinson's disease in PC12 cells by inhibiting inflammation, oxidative stress and cell apoptosis.

Salidroside protects PC12 cells from MPP⁺-induced apoptosis via activation of the PI3K/Akt pathway.

Salidroside Protects Dopaminergic Neurons by Regulating the Mitochondrial MEF2D-ND6 Pathway in the MPTP/MPP+ -Induced Model of Parkinson's Disease.

Neuroprotective effect of salidroside against 6-OHDA-induced oxidative stress in PC12 cells

Salvianolic Acid B Protects SH-SY5Y Neuroblastoma Cells from 1-Methyl-4-phenylpyridinium-induced Apoptosis.

Salvianolic acid B protects against MPP+-induced neuronal injury via repressing oxidative stress and restoring mitochondrial function

Salsolinol Induces Parkinson's Disease Through Activating NLRP3-Dependent Pyroptosis and the Neuroprotective Effect of Acteoside

Salidroside Protects SH‑SY5Y from Pathogenic Α‑synuclein by Promoting Cell Autophagy Via Mediation of Mtor/p70s6k Signaling.

Salidroside Ameliorates Parkinson's Disease by Inhibiting NLRP3-dependent Pyroptosis

Salidroside improves cognitive function in Parkinson's disease via Braf-mediated mitogen‐activated protein kinase signaling pathway

Acteoside Alleviates Salsolinol-Induced Parkinson's Disease by Inhibiting Ferroptosis Via Activating Nrf2/SLC7A11/GPX4 Pathway

Salidroside Protects Against 6-Hydroxydopamine-induced Cytotoxicity by Attenuating ER Stress

Salsolinol Protects SH-SY5Y Cells Against MPP+ Damage and Increases Enteric S100-Immunoreactivity in Wistar Rats

Endoplasmic Reticulum Stress And Nf-Kappa B Pathway In Salidroside Mediated Neuroprotection: Potential Of Salidroside In Neurodegenerative Diseases

Salidroside attenuates cerebral ischemia/reperfusion injury by regulating TSC2-induced autophagy

Salidroside Improves Brain Ischemic Injury by Activating PI3K/Akt Pathway and Reduces Complications Induced by Delayed Tpa Treatment.

Salidroside Promotes the Pathological Α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells

Effect of Salidroside on PI3K/protein kinase B signaling in Parkinson's disease model mice

Salidroside Provides Neuroprotection by Modulating Microglial Polarization after Cerebral Ischemia.

Neuroprotective Effects of Salidroside in the PC12 Cell Model Exposed to Hypoglycemia and Serum Limitation

[Salidroside Protects PC12 Cells from H2O2-induced Apoptosis Via Suppressing NOX2-ROS-MAPKs Signaling Pathway].